These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. HIV Broadly Neutralizing Antibodies Expressed as IgG3 Preserve Neutralization Potency and Show Improved Fc Effector Function. Richardson SI; Ayres F; Manamela NP; Oosthuysen B; Makhado Z; Lambson BE; Morris L; Moore PL Front Immunol; 2021; 12():733958. PubMed ID: 34566999 [TBL] [Abstract][Full Text] [Related]
3. Administration of anti-HIV-1 broadly neutralizing monoclonal antibodies with increased affinity to Fcγ receptors during acute SHIV Dias J; Fabozzi G; Fourati S; Chen X; Liu C; Ambrozak DR; Ransier A; Laboune F; Hu J; Shi W; March K; Maximova AA; Schmidt SD; Samsel J; Talana CA; Ernste K; Ko SH; Lucas ME; Radecki PE; Boswell KL; Nishimura Y; Todd JP; Martin MA; Petrovas C; Boritz EA; Doria-Rose NA; Douek DC; Sékaly RP; Lifson JD; Asokan M; Gama L; Mascola JR; Pegu A; Koup RA Nat Commun; 2024 Aug; 15(1):7461. PubMed ID: 39198422 [TBL] [Abstract][Full Text] [Related]
4. Broadly Neutralizing Antibodies Display Potential for Prevention of HIV-1 Infection of Mucosal Tissue Superior to That of Nonneutralizing Antibodies. Cheeseman HM; Olejniczak NJ; Rogers PM; Evans AB; King DFL; Ziprin P; Liao HX; Haynes BF; Shattock RJ J Virol; 2017 Jan; 91(1):. PubMed ID: 27795431 [TBL] [Abstract][Full Text] [Related]
5. Rational Engraftment of Quaternary-Interactive Acidic Loops for Anti-HIV-1 Antibody Improvement. Liu Q; Zhang P; Miao H; Lin Y; Kwon YD; Kwong PD; Rikhtegaran-Tehrani Z; Seaman MS; DeVico AL; Sajadi MM; Lusso P J Virol; 2021 May; 95(12):. PubMed ID: 33827946 [TBL] [Abstract][Full Text] [Related]
6. Immunization of cows with HIV envelope trimers generates broadly neutralizing antibodies to the V2-apex from the ultralong CDRH3 repertoire. Altman PX; Ozorowski G; Stanfield RL; Haakenson J; Appel M; Parren M; Lee WH; Sang H; Woehl J; Saye-Francisco K; Sewall LM; Joyce C; Song G; Porter K; Landais E; Andrabi R; Wilson IA; Ward AB; Mwangi W; Smider VV; Burton DR; Sok D PLoS Pathog; 2024 Sep; 20(9):e1012042. PubMed ID: 39250525 [TBL] [Abstract][Full Text] [Related]
7. Polyclonal Broadly Neutralizing Antibody Activity Characterized by CD4 Binding Site and V3-Glycan Antibodies in a Subset of HIV-1 Virus Controllers. Nyanhete TE; Edwards RJ; LaBranche CC; Mansouri K; Eaton A; Dennison SM; Saunders KO; Goodman D; Janowska K; Spreng RL; Zhang L; Mudrak SV; Hope TJ; Hora B; Bradley T; Georgiev IS; Montefiori DC; Acharya P; Tomaras GD Front Immunol; 2021; 12():670561. PubMed ID: 35003053 [TBL] [Abstract][Full Text] [Related]
8. IgG3 enhances neutralization potency and Fc effector function of an HIV V2-specific broadly neutralizing antibody. Richardson SI; Lambson BE; Crowley AR; Bashirova A; Scheepers C; Garrett N; Abdool Karim S; Mkhize NN; Carrington M; Ackerman ME; Moore PL; Morris L PLoS Pathog; 2019 Dec; 15(12):e1008064. PubMed ID: 31841557 [TBL] [Abstract][Full Text] [Related]
9. Distinct Immunoglobulin Fc Glycosylation Patterns Are Associated with Disease Nonprogression and Broadly Neutralizing Antibody Responses in Children with HIV Infection. Muenchhoff M; Chung AW; Roider J; Dugast AS; Richardson S; Kløverpris H; Leslie A; Ndung'u T; Moore P; Alter G; Goulder PJR mSphere; 2020 Dec; 5(6):. PubMed ID: 33361123 [TBL] [Abstract][Full Text] [Related]
10. HIV-specific Fc effector function early in infection predicts the development of broadly neutralizing antibodies. Richardson SI; Chung AW; Natarajan H; Mabvakure B; Mkhize NN; Garrett N; Abdool Karim S; Moore PL; Ackerman ME; Alter G; Morris L PLoS Pathog; 2018 Apr; 14(4):e1006987. PubMed ID: 29630668 [TBL] [Abstract][Full Text] [Related]
11. Afucosylated broadly neutralizing antibodies enhance clearance of HIV-1 infected cells through cell-mediated killing. de Taeye SW; Schriek AI; Umotoy JC; Grobben M; Burger JA; Sanders RW; Vidarsson G; Wuhrer M; Falck D; Kootstra NA; van Gils MJ Commun Biol; 2024 Aug; 7(1):964. PubMed ID: 39122901 [TBL] [Abstract][Full Text] [Related]
12. Enhancing HIV-1 Neutralization by Increasing the Local Concentration of Membrane-Proximal External Region-Directed Broadly Neutralizing Antibodies. Kim S; Filsinger Interrante MV; Kim PS J Virol; 2023 Jan; 97(1):e0164722. PubMed ID: 36541800 [TBL] [Abstract][Full Text] [Related]
13. Complementary Roles of Antibody Heavy and Light Chain Somatic Hypermutation in Conferring Breadth and Potency to the HIV-1-Specific CAP256-VRC26 bNAb Lineage. Sacks D; Wiehe K; Morris L; Moore PL J Virol; 2022 May; 96(10):e0027022. PubMed ID: 35510865 [TBL] [Abstract][Full Text] [Related]
14. Enhanced Ability of Plant-Derived PGT121 Glycovariants To Eliminate HIV-1-Infected Cells. Anand SP; Ding S; Tolbert WD; Prévost J; Richard J; Gil HM; Gendron-Lepage G; Cheung WF; Wang H; Pastora R; Saxena H; Wakarchuk W; Medjahed H; Wines BD; Hogarth M; Shaw GM; Martin MA; Burton DR; Hangartner L; Evans DT; Pazgier M; Cossar D; McLean MD; Finzi A J Virol; 2021 Aug; 95(18):e0079621. PubMed ID: 34232070 [TBL] [Abstract][Full Text] [Related]
15. Systematic Assessment of Antiviral Potency, Breadth, and Synergy of Triple Broadly Neutralizing Antibody Combinations against Simian-Human Immunodeficiency Viruses. Berendam SJ; Styles TM; Morgan-Asiedu PK; Tenney D; Kumar A; Obregon-Perko V; Bar KJ; Saunders KO; Santra S; De Paris K; Tomaras GD; Chahroudi A; Permar SR; Amara RR; Fouda GG J Virol; 2021 Jan; 95(3):. PubMed ID: 33177194 [TBL] [Abstract][Full Text] [Related]
16. Broad and ultra-potent cross-clade neutralization of HIV-1 by a vaccine-induced CD4 binding site bovine antibody. Heydarchi B; Fong DS; Gao H; Salazar-Quiroz NA; Edwards JM; Gonelli CA; Grimley S; Aktepe TE; Mackenzie C; Wales WJ; van Gils MJ; Cupo A; Rouiller I; Gooley PR; Moore JP; Sanders RW; Montefiori D; Sethi A; Purcell DFJ Cell Rep Med; 2022 May; 3(5):100635. PubMed ID: 35584627 [TBL] [Abstract][Full Text] [Related]